Vesicular stomatitis virus modified with single chain IL-23 exhibits oncolytic activity against tumor cells in vitro and in vivo

References

• Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30.
   PubMed Web of Science ®Google Scholar
• Tseng JC, Levin B, Hurtado A, et al. Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol. 2004;22:70–77.
   PubMed Web of Science ®Google Scholar
• Vigil A, Park MS, Martinez O, et al. Use of reverse genetics to enhance the oncolytic properties of newcastle disease virus. Cancer Res. 2007;67:8285–8292.
   PubMed Web of Science ®Google Scholar
• Hu JCC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEX(GM-CSF), a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12:6737–6747.
   PubMed Web of Science ®Google Scholar
• Barber GN. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 2004;17:516–527.
   PubMed Web of Science ®Google Scholar
• Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821–825.
   PubMed Web of Science ®Google Scholar
• Ebert O, Harbaran S, Shinozaki K, Woo SL. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther. 2005;12:350–358.
   PubMed Web of Science ®Google Scholar
• Huang TG, Ebert O, Shinozaki K, Garcia-Sastre A, Woo SLC. Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol Ther. 2003;8:434–440.
   PubMed Web of Science ®Google Scholar
• Shi W, Tang QQ, Chen XC, et al. Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer. J Mol Med. 2009;87:493–506.
   Web of Science ®Google Scholar
• Gao Y, Whitaker-Dowling P, Griffin JA, Barmada MA, Bergman I. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors. Cancer Gene Ther. 2009;16:44–52.
   Web of Science ®Google Scholar
• Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or Myc function and involves the induction of apoptosis. J Virol. 2001;75:3474–3479.
   PubMed Web of Science ®Google Scholar
• Huszthy PC, Giroglou T, Tsinkalovsky O, et al. Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLoS One. 2009;4:e6314.
   PubMed Web of Science ®Google Scholar
• Tumilasci VF, Oliere S, Nguyen TLA, Shamy A, Bell J, Hiscott J. Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol. 2008;82:8487–8499.
   Web of Science ®Google Scholar
• Cesaire R, Oliere S, Sharif-Askari E, et al. Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia. Oncogene. 2006;25:349–358.
   Web of Science ®Google Scholar
• Shinozaki K, Ebert O, Woo SLC. Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus. Int J Cancer. 2005;114:659–664.
   Web of Science ®Google Scholar
• Shinozaki K, Ebert O, Kournioti C, Tai YS, Woo SLC. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther. 2004;9:368–376.
   Web of Science ®Google Scholar
• Altomonte J, Braren R, Schulz S, et al. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology. 2008;48:1864–1873.
   Web of Science ®Google Scholar
• Feng Y, He G, Wu Y, Wen Y. [Effect of apoptosis of vesicular stomatitis virus on tumor cells of nasopharyngeal carcinoma in vivo]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008;22:995–997.
   Google Scholar
• Hadaschik BA, Zhang K, So AI, et al. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res. 2008;68:4506–4510.
   PubMed Web of Science ®Google Scholar
• Hadaschik BA, Zhang K, So AI, et al. Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer. Urologe. 2008;47:1145–1151.
   Web of Science ®Google Scholar
• Balachandran S, Barber GN. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life. 2000;50:135–138.
   PubMed Web of Science ®Google Scholar
• Johnson KM, Vogel JE, Peralta PH. Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am JTrop MedHyg. 1966;15:244–246.
   PubMed Web of Science ®Google Scholar
• Fields BN, Hawkins K. Human infection with the virus of vesicular stomatitis during an epizootic. N Engl J Med. 1967;277:989–994.
   PubMed Web of Science ®Google Scholar
• Rose JK, Whitt MA. Rhabdoviridae: the viruses and their replication. In: Knipe DM, P.M. H, eds. Fields Virology. Philadelphia, PA: Lippincott Williams and Wilkins, 2001:1221–1242.
   Google Scholar
• Ebert O, Shinozaki K, Kournioti C, Park MS, Garcia-Sastre A, Woo SLc. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res. 2004;9:S397–S397.
   Google Scholar
• Shin EJ, Wanna GB, Choi B, et al. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope. 2007;117:210–214.
   PubMed Web of Science ®Google Scholar
• Wollmann G, Robek MD, van den Pol AN. Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J Virol. 2007;81:1479–1491.
   Web of Science ®Google Scholar
• Connor JH, Naczki C, Koumenis C, Lyles DS. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol. 2004;78:8960–8970.
   Web of Science ®Google Scholar
• Iwaki H, Barnavon Y, Bash JA, Wallack MK. Vaccinia virus-infected C-C36 colon-tumor cell lysates stimulate cellular-responses in vitro and protect syngeneic balb/c mice from tumor-cell challenge. J Surg Oncol. 1989;40:90–96.
   PubMed Web of Science ®Google Scholar
• Liu L, Chavan R, Feinberg MB. Dendritic cells are preferentially targeted among hematolymphocytes by modified vaccinia virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol. 2008;9:15.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006;7:131–137.
   PubMed Web of Science ®Google Scholar
• Rowland-Jones S, Dong T. Dying T cells trigger autoimmunity in HIV. Nat Med. 2007;13:1413–1415.
   Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699–708.
   PubMed Web of Science ®Google Scholar
• Bastos KRB, Marinho CRF, Barboza R, Russo M, Alvarez JM, Lima MRD. What kind of message does IL-12/IL-23 bring to macrophages and dendritic cells? Microbes Infect. 2004;6:630–636.
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor ROR gamma t directs the differentiation program of proinflammatory IL-17(+) T helper cells. Cell. 2006;126:1121–1133.
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–725.
   PubMed Web of Science ®Google Scholar
• McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006;27:17–23.
   PubMed Web of Science ®Google Scholar
• Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol. 2007;178:7571–7580.
   PubMed Web of Science ®Google Scholar
• Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther. 1995;2:96–106.
   PubMed Web of Science ®Google Scholar
• Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 1994;153:1697–1706.
   PubMed Web of Science ®Google Scholar
• Lo CH, Lee SC, Wu PY, et al. Antitumor and antimetastatic activity of IL-23. J Immunol. 2003;171:600–607.
   PubMed Web of Science ®Google Scholar
• Cohen J. IL-12 deaths: explanation and a puzzle. Science. 1995;270:908.
   PubMed Web of Science ®Google Scholar
• Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol. 1999;27:58–63.
   PubMed Web of Science ®Google Scholar
• Overwijk WW, de Visser KE, Tirion FH, et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol. 2006;176:5213–5222.
   PubMed Web of Science ®Google Scholar
• Hao JS, Shan BE. Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol Immunother. 2006;55:1426–1431.
   PubMed Web of Science ®Google Scholar
• Liu L, Shan B, Feng Y. Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus. Cell Immunol. 2009;258:181–187.
   Web of Science ®Google Scholar
• Miller JM, Bidula SM, Jensen TM, Reiss CS. Cytokine-modified VSV is highly attenuated for neural pathology but is both highly immunogenic and oncolytic. International Journal of Interferon, Cytokine and Mediator Research. 2009;1:15–32.
   Google Scholar
• Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A. 1995;92:4477–4481.
   Web of Science ®Google Scholar
• Tseng JC, Granot T, DiGiacomo V, Levin B, Meruelo D. Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor. Cancer Gene Ther. 2010;17:244–255.
   PubMed Web of Science ®Google Scholar